European market guides
How healthcare tenders work, market by market
Each European country buys medicines and medical devices differently. These guides explain who buys in each market, through which procurement route, what tends to decide awards, and what is published and what is not. All 27 EU countries are refreshed daily in the platform, together with the UK, Norway and Switzerland.
Choose a market
Country guides
Select a country on the map or from the list. Markets without a dedicated guide are still covered in full in the platform.
RGS covers what buyers publish. Some prices are never published anywhere, such as insurer discounts and negotiated hospital deals; for those we set up a private pipeline with your own bids, results and price lists, visible only to your team.
At a glance
Who buys, and how, by market
| Market | Main buyers | Main routes |
|---|---|---|
| Germany | Statutory health insurers (AOK, TK, BARMER, DAK, IKK and BKK groups); hospital purchasing groups; public university and municipal hospitals | Discount contracts (Rabattverträge) for outpatient generics and biosimilars; hospital tenders and purchasing-group contracts; open-house contracts that any supplier can join |
| France | UniHA, Resah and AGEPS (AP-HP); regional hospital groups (GHT); UGAP for some categories | Framework agreements (accords-cadres) and marchés by lot, often national in scope; regional GHT tenders |
| Italy | Regional central purchasing bodies (for example ARIA, SoReSa, Intercent-ER, ESTAR, Azienda Zero); local health authorities and hospitals below the threshold | Regional tenders by lot; framework agreements (accordo quadro), which for biosimilars include several ranked suppliers |
| Spain | INGESA (national centralised purchasing); regional health services such as SAS, SERMAS, CatSalut and ICS, Osakidetza and SERGAS; individual hospitals | National framework agreements, for example for biosimilars; regional and hospital tenders by lot |
| Netherlands | Health insurers for outpatient medicines; hospitals and hospital purchasing groups for inpatient and specialist medicines | Insurer preference policy (selection rounds, not public tenders); university hospital tenders; negotiated hospital contracts |
| Belgium | Individual hospitals and loco-regional hospital networks; joint tenders between hospitals | Hospital tenders by lot and framework agreements |
| United Kingdom | National NHS commercial teams (the Commercial Medicines Unit) for hospital medicines; NHS Supply Chain for devices and consumables; NHS National Services Scotland; NHS Wales Shared Services Partnership | National generics and biosimilar frameworks in waves, split by region; device frameworks |
| Nordics | Amgros (Denmark); Sykehusinnkjøp HF (Norway); the Swedish regions, often jointly by healthcare region; Finnish wellbeing services counties and their joint purchasing units | National or regional hospital tenders by product; joint Nordic tenders for off-patent hospital medicines; Sweden's pharmacy generics follow a monthly lowest-price system |
| Austria and Switzerland | Austria: the state hospital operators and the Bundesbeschaffung GmbH (BBG) for selected medicines. Switzerland: cantonal and university hospitals and their purchasing groups | Austria: open tenders and many negotiated procedures. Switzerland: hospital tenders by lot under the revised federal and cantonal procurement rules |
| Portugal, Ireland and Greece | Portugal: SPMS and the 39 local health units (ULS) formed in 2024. Ireland: the Health Service Executive. Greece: EKAPY and public hospitals | Portugal: central framework agreements and ULS tenders. Ireland: a dynamic purchasing system for authorised medicines. Greece: central EKAPY tenders and negotiations |
| Central and Eastern Europe | Individual public hospitals; national central purchasing in Romania and Hungary; the health insurers in Czechia from 2026 | Hospital tenders by lot; dynamic purchasing systems; national framework agreements |
New to European medicine tenders? Start with how pharmaceutical tenders work in Europe , see the main medicine buyers per market or read what the Critical Medicines Act would change
Buyer structures change. These guides describe the main routes as of 2026; the platform tracks individual buyers and notices continuously.
Track these markets on one calendar
The calendar, award database and pricing model cover Europe in a single view.